The Renin-Angiotensin System (RAS) medicine sales in Canada are forecasted to decline steadily from 2024 to 2028. The sales value starts at 569.1 million USD in 2024 and drops to 386.6 million USD by 2028. This represents a consistent negative year-on-year variation. The Compound Annual Growth Rate (CAGR) over the five-year period is negative, indicating a contraction in the market.

Future trends to watch include:

The impact of emerging alternative treatments and generics on RAS medicine sales.
Regulatory changes affecting the pharmaceutical market in Canada.
Evolution of healthcare policies and their influence on drug reimbursement and accessibility.